Skip to Content
MilliporeSigma
All Photos(1)

Documents

P2698000

Prednicarbate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(11β)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-21-(1-oxopropoxy)pregna-1,4-diene-3,20-dione

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H36O8
CAS Number:
73771-04-7
Molecular Weight:
488.57
EC Number:
277-590-3
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

prednicarbate

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

InChI

1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3

InChI key

FNPXMHRZILFCKX-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Prednicarbate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001630

Prednicarbate for system suitability A, European Pharmacopoeia (EP) Reference Standard

1554909

Prednicarbate, United States Pharmacopeia (USP) Reference Standard

1554910

Prednicarbate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1554931

Prednicarbate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1554920

Prednicarbate Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0002231

Prednicarbate for peak identification, CRS, European Pharmacopoeia (EP) Reference Standard

PHR3101

Prednicarbate, pharmaceutical secondary standard, certified reference material

PHR3102

Prednicarbate Related Compound C, pharmaceutical secondary standard, certified reference material

pictograms

Health hazard
GHS08

signalword

Danger

hcodes

H360D

Hazard Classifications

Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Aditya K Gupta et al.
Journal of drugs in dermatology : JDD, 3(5), 553-556 (2004-11-24)
Prednicarbate is a non-halogenated, double-ester derivative of prednisolone that has become of interest for the treatment of inflammatory skin diseases, for example atopic dermatitis. In the past, topical steroids have been a popular choice for treating these diseases; however, the
Kerstin Katzer et al.
European journal of dermatology : EJD, 20(1), 82-84 (2009-10-03)
The epidermal growth factor receptor (EGFR) inhibitor cetuximab is used to treat advanced stages of solid tumors. Acneiform skin eruptions, the most common side effects of cetuximab, stigmatize the patient in daily life and may lower compliance. As oral treatment
Aditya K Gupta et al.
Journal of cutaneous medicine and surgery, 8(4), 244-247 (2005-08-11)
Topical steroids have been a popular choice for treating various cutaneous disorders; however, the potential for significant local and systemic adverse events, like skin atrophy and hypothalamic-pituitary-adrenal (HPA) axis suppression, has limited their use. This article reviews the topical steroid
V Niemeier et al.
The Journal of dermatological treatment, 16(2), 95-101 (2005-07-16)
The treatment of atopic dermatitis still remains a challenge. Little research has been done on the issue of the extent to which patients correctly use prescribed topical preparations under everyday conditions. To investigate what quantity of topical preparations is applied
Grover's disease associated with pregnancy.
Eui Hyung Lee et al.
The Journal of dermatology, 37(4), 381-383 (2010-05-29)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service